Table of Content


COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
Eli Lilly and Company - Key Company Facts 8
Eli Lilly and Company - Company Description 9
Eli Lilly and Company - Top Executives 10
Eli Lilly and Company- Top Executives Biographies 11
Eli Lilly and Company- Head Office & Locations 15
Head Office - Country 15
Key Subsidiaries 16
Key Joint Ventures 18
Eli Lilly and Company - Products and Services 19
Products 19
Eli Lilly and Company - Historic Events 20
Eli Lilly and Company - Company’s Management Discussion 23
Eli Lilly and Company - Company’s Mission and Vision 29
Mission 29
Vision 29
Eli Lilly and Company - Corporate Strategy 30
Eli Lilly and Company - Business Description 34
Human Pharmaceutical 35
Eli Lilly and Company - ESG Spotlight 37
Environment 39
Social 39
Corporate Governance 40
Eli Lilly and Company - SWOT Analysis 41
Overview 41
Strengths 43
Weaknesses 46
Opportunities 47
Threats 50
Eli Lilly and Company - PESTLE Analysis 53
Overview 53
Political Factors 55
Economic Factors 57
Social Factors 59
Technological Factors 60
Legal Factors 62
Environmental Factors 64
Eli Lilly and Company - Financial Deep Dive 65
Share Price Trend - Oct-2023to Oct-2024 (Average Share Closing Price) 65
Profit and Loss Statement 67
Summary of Profit and Loss Statement 67
Balance Sheet 69
Summary of Balance Sheet 69
Cash Flow Statement 71
Summary of Cash Flow Statement 71
Key Financial Ratio Analysis 73
Eli Lilly and Company - Ratio Charts 74
Activity Ratio Charts 74
Growth Ratios Charts 75
Leverage Ratio Charts 76
Liquidity Ratio Charts 76
Profitability Ratio Charts 78
Competing Players 79
Snapshot of Competing Players 80
AbbVie Inc 80
Key Company Facts 80
Company Description 80
Snapshot of Competing Players 82
Johnson & Johnson 82
Key Company Facts 82
Company Description 82
Snapshot of Competing Players 84
Merck KGaA 84
Key Company Facts 84
Company Description 84
Snapshot of Competing Players 86
Novartis AG 86
Key Company Facts 86
Company Description 86
Snapshot of Competing Players 88
Pfizer Inc. 88
Key Company Facts 88
Company Description 88
Eli Lilly and Company - In the News 90
02-Oct-2024- Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials 90
25-Sep-2024- New data show Lilly’s EBGLYSS (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis 92
24-Sep-2024- Lilly’s Kisunla (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer’s Disease 94
13-Sep-2024- FDA Approves Lilly’s EBGLYSS? (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis 96
12-Sep-2024- Lilly expands manufacturing footprint in Ireland with $1.8 billion investment 98
10-Sep-2024- With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes 100
03-Oct-2023- Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies 102
22-Sep-2023- US FDA approves Jardiance? for the treatment of adults with chronic kidney disease 104
22-Aug-2023- Lilly’s Retevmo? (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer 106
04-Aug-2023- Lilly’s Retevmo? (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer 108
14-Jul-2023- Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases 110
21-Jun-2023- US FDA approves Jardiance? (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older 110
17-Apr-2023- Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities 113
08-Mar-2023- Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer’s Disease 115
13-Feb-2023- Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh 118
24-Jan-2023- Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park 120
Eli Lilly and Company- Key Deals 122

30-Aug-2023 - Lilly quietly completes purchase of Padcev competitor, estimated at nearly half a billion dollars 122
14-Aug-2023 - Lilly Completes Acquisition of Versanis Bio 123
14-Aug-2023 - Lilly Completes Acquisition of Sigilon Therapeutics 123
09-Aug-2023 - Lilly Completes Acquisition of DICE Therapeutics 125
27-Jul-2023 - CHEPLAPHARM successfully closes acquisition of Zyprexa? portfolio 125
29-Jun-2023 - Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics 126
01-Dec-2022 - Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases 127
14-Jul-2021 - Lilly acquires biotech firm Protomer Technologies for $1bn 129
13-Jan-2014 - Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics 129
Appendix 131
Definitions 131
SWOT Analysis 131
PESTLE Analysis 131
Value Chain Analysis 131
ESG Spotlight 131
Financial Deep Dive 131
Financial Ratios - 132
Activity Ratios 132
Growth Ratios 133
Leverage Ratios 134
Liquidity Ratios 135
Market Ratios 136
Profitability Ratios 136
Research Methodology 137
Disclaimer 138
Contact Us 138



List of Figures

Charts
Figure 1: Eli Lilly and Company- SWOT Analysis 42
Figure 2: Eli Lilly and Company - PESTLE Analysis 54
Figure 3: Eli Lilly and Company - Average Share Price Trend - Oct-2023 to Oct-2024 66
Figure 4: Eli Lilly and Company - Profit and Loss Statement - 2020-2023 68
Figure 5: Eli Lilly and Company - Balance Sheet - 2020-2023 70
Figure 6: Eli Lilly and Company - Cash Flow Statement 2020-2023 72
Figure 7: Eli Lilly and Company - Activity Ratio Charts 74
Figure 8: Eli Lilly and Company - Growth Ratio Charts (Value %) 75
Figure 9: Eli Lilly and Company - Leverage Ratio Charts 76
Figure 10: Eli Lilly and Company - Liquidity Ratio Charts 77
Figure 11: Eli Lilly and Company - Profitability Ratio Charts (Value %) 78
Figure 12: Competing Players - AbbVie Inc - Key Financials 81
Figure 13: Competing Players - Johnson & Johnson - Key Financials 83
Figure 14: Competing Players - Merck KGaA - Key Financials 85
Figure 15: Competing Players - Novartis AG - Key Financials 87
Figure 16: Competing Players - Pfizer Inc. - Key Financials 89

List of Tables

Tables
Table 1: Eli Lilly and Company - Company Facts
Table 2: Eli Lilly and Company - Top Executives
Table 3: Eli Lilly and Company - Top Executives Biographies
Table 4: Eli Lilly and Company - Subsidiaries
Table 5: Eli Lilly and Company - Key Joint Ventures
Table 6: Eli Lilly and Company - Products
Table 7: Eli Lilly and Company - Historic Events
Table 8: Eli Lilly and Company - Share Price Trend - Oct-2023 to Oct-2024
Table 9: Eli Lilly and Company- Ratio Analysis - 2020-2023
Table 10: Eli Lilly and Company -Competing Players